Return to Clinical Trials Search Results

A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)

Primary Objectives Objective: Within each platinum doublet chemotherapy cohort, evaluate the percentage of participants who develop Grade 3 or higher pneumonitis Objective: Within each platinum doublet chemotherapy cohort, estimate the ORR as assessed by BICR according to RECIST 1.1 Secondary Objectives Objective: Within each platinum doublet chemotherapy cohort, evaluate the PFS assessed by BICR according to RECIST 1.1 Objective: Within each platinum doublet chemotherapy cohort, evaluate OS Objective: Within each platinum doublet chemotherapy cohort, evaluate the safety and tolerability of each treatment regimen by the percentage of participants who develop AEs Tertiary/Exploratory Objectives Objective: Within each platinum doublet chemotherapy cohort, evaluate OS and distant metastases per RECIST 1.1 based on BICR Objective: To identify molecular (genomic, metabolic and/or proteomic) biomarkers that may be indicative of clinical response/resistance, safety, pharmacodynamic activity, and/or the mechanism of action of pembrolizumab in combination with platinum doublet chemotherapy and radiotherapy

Phase

II

Recruitment Status

Past Studies

View on
ClinicalTrials.gov